RxDoctor Payments DataLook up a doctor →

Nicole Fram, MD

Ophthalmology · Los Angeles, CANPI 1114140795

Payments from drug & device makers

$1,236,906in general payments, 2019–2025

Across 875 payments — averaging $1413.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$480K
  • Alcon$189K
  • Alcon Research LLC$151K
  • Beaver-visitec International, Inc.$106K
  • AbbVie$77K
  • Carl Zeiss Meditec, Inc.$69K
  • plus $166K from 36 others

What the payments were for

  • Consulting fees$429,25378%
  • Speaking & faculty fees$80,82315%
  • Travel & lodging$9,5182%
  • Food & beverage$29,1415%
  • Charitable contribution$2,5000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,236,906 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$691,317
Medicare patients
914
Services billed
4,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine148$123,401
ProlensaBromfenac Sodium200$68,131
XiidraLifitegrast40$39,597
XdemvyLotilaner21$39,405
MieboPerfluorohexyloctane/Pf43$32,635
Bromfenac Sodium179$31,942
Prednisolone Acetate584$29,441
Cyclosporine86$20,309
Lotemax SmLoteprednol Etabonate73$19,466
CombiganBrimonidine Tartrate/Timolol26$14,231
LumiganBimatoprost19$12,283
Loteprednol Etabonate90$11,676
IlevroNepafenac32$11,606
CequaCyclosporine16$11,585
MoxifloxacinMoxifloxacin Hcl551$10,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan, Restasis Multidose, Alphagan P$77,097$162,481220 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate, Lotemax$5,137$103,962377 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$5,421$72,23283 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$52,241$39,40521 claims
NovartisIlevro$6,723$11,60632 claims
Sun Pharmaceutical Industries Inc.Cequa$1,351$11,58516 claims
AlconSimbrinza$188,509$4,79721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →